The FDA has granted priority review to a supplemental new drug application (sNDA) for use of dabrafenib (Tafinlar) and trametinib (Mekinist) in combination as an adjuvant treatment for patients with BRAFV600E– or V600K–positive stage III melanoma following complete resection.
Non-alcoholic fatty liver disease (NAFLD) is a risk factor for cancer, according to a recent report about a 7.5-year Korean study.
The FDA has approved a novel breast-specific stereotactic body radiotherapy (SBRT) device known as GammaPod as a treatment for patients with early breast cancer, based on findings from a 17-patient study.
The FDA has granted a priority review to a new drug application (NDA) for apalutamide (ARN-509) for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). Apalutamide is an oral androgen receptor inhibitor.
Mothaffar Fahed Rimawi, MD, explains the importance of targeting treatments for patients with low levels of HER2 protein based on their genetic mutations, and the possible use of immunotherapy for these patients.
The FDA has approved the combination of pertuzumab (Perjeta), trastuzumab (Herceptin) and chemotherapy as an adjuvant treatment for patients with HER2-positive early breast cancer at high risk for recurrence.
Nivolumab (Opdivo) is now approved by the Food and Drug Administration (FDA) as an adjuvant treatment for patients with completely resected melanoma with lymph node involvement or metastatic disease.
Based on findings from the phase III BFORE trial, the FDA has approved Bosutinib as a first-line treatment for a chronic myeloid leukemia subtype.
The FDA approved abozantinib (Cabometyx) for use in previously untreated patients who have advanced renal cell carcinoma (RCC).
Using oral rivaroxaban (Xarelto) to treat patients with cancer reduced venous thromboembolism (VTE) recurrence in a select-d trial.
The FDA has granted a priority review to a supplemental new drug application (sNDA) for the use of osimertinib as a first-line treatment for patients with non-small cell lung cancer (NSCLC) whose tumors harbor EGFR mutations.
Patients with cancer who suffer severe distress are more likely to miss appointments during the course of their radiation therapy and be admitted to the hospital.
New trial results represent the first successful effort in more than 30 years to imrove outcomes of first-line treatment in patients with advanced Hodgkin lymphoma (HL).
The FDA has granted a priority review to a supplemental biologics license application (sBLA) for use of this combination as a frontline treatment for intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC).
A novel approach to the treatment of patients with smoldering multiple myeloma (SMM) produced durable results in a phase II trial.
Results of a phase I trial presented showed that the agent BLU-285 (Avapritinib) agent was well tolerated among patients with an advanced or aggressive form of systemic mastocytosis (ASM), a rare blood disorder that originates in mast cells.
Results of a new study show that adding ribociclib (Kisqali) to standard endocrine therapy with temporary ovarian suppression significantly improved progression-free survival (PFS) when used as a first-line treatment for
A supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) has been granted FDA priority review status for the treatment of adults and children with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBCL).
The American Society of Clinical Oncology (ASCO) recently published a special article in the Journal of Clinical Oncology that idicated that even one alcoholic drink per day can increase cancer risk.
This PARP inhibitor therapy is more effective than chemotherapy in extending progression-free survival and reducing risk of death from BRCA-positive breast cancer.
Shortening the intervals between chemotherapy cycles or administering the drugs sequentially compared to current techniques reduces early-stage breast cancer recurrence and mortality, study shows.
PARP inhibitor Rucaparib may soon be available to a wider group of patients with ovarian cancer.
Bevacizumab (Avastin), a VEGF inhibitor, has been granted a full approval by the FDA for the treatment of adult patients with glioblastoma that progressed following prior therapy, according to its manufacturer, Genentech.
The researchers found that job lock was more common among survivors reporting previous health insurance denial and difficulties paying medical bills. Job lock was also more frequent among women and in survivors who had a severe, disabling, or life-threatening health condition.
Trastuzumab (Herceptin) biosimilar MYL-1401O (Ogivri; trastuzumab-dkst), which is co-developed by Mylan and Biocon, has just been approved by the FDA for HER2-positive patients with breast cancer or metastatic gastric or gastroesophageal junction adenocarcinoma, the same indications as trastuzumab.
Most people surveyed think that the cost of cancer care is too high, and some even reported taking action that could jeopardize the outcomes of their treatments to bring the cost down.
The FDA has granted a priority review to a biologics license application (BLA) for mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have received at least 1 prior systemic therapy, according to Kyowa Hakko Kirin, the manufacturer of the anti-CCR4 monoclonal antibody.
Although much success has been seen, 15% of patients with HER2-positive breast cancer will recur. Outcomes for those patients need to be improved, said Sara M. Tolaney, MD.
“Immunotherapy is a new option for patients and is well established,” said George R. Blumenschein, MD. “We are refining how we use it. There will be a number of additional refinements as we have the new data that will be coming forward in the next few months.”
Three CDK 4/6 inhibitors—palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio)— are game-changers in the field of breast cancer, explained Richard S. Finn, MD.
